Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)


4SC AG*
(Germany)

Boehringer Ingelheim GmbH (Germany)

Research agreement to identify ligands as the basis for drug discovery against three undisclosed targets

4SC will use its virtual high-throughput screening technology, 4Scan, to screen a pool of about 3.3M small organic molecules; 4SC will provide the most potent compounds in return for up-front and research payments (2/25)

Abgenix Inc.
(ABGX)

Chugai Pharmaceutical
Co. Ltd. (Japan)

Multiyear collaboration to develop fully human monoclonal antibody therapies

Chugai also gained rights to develop pro-ducts based on patents belonging to Abgenix; Abgenix will receive an up-front technology utilization payment and a licensing fee; the companies will share equally in the development and commercialization costs of all therapeutic antibody products that are designated as joint development antigens; any future profits resulting from the collaboration also will be shared equally on a worldwide basis (2/3)

A. Carlsson Research AB* (Sweden)

Merck & Co.
Inc.

Collaboration granting Merck a license to compounds from Carlsson Research's dopamine stabilizer program

Carlsson Research will receive an up-front payment of €8M (US$8.8M) (3/10)

Aclara
BioSciences
Inc.
(ACLA)

Procter &
Gamble Co.

Agreement under which P&G will gain access to Aclara's eTag Assay System for use in research and development activities

The agreement will include eTag assay products and services for multiplexed assays to monitor expression of genes as well as proteins (1/23)

ActivX
Biosciences
Inc.*

Sosei Co.
Ltd. (Japan)

Collaboration to identify potential new target indications for candidate drug molecules from Sosei's Drug Re-profiling Platform collection

Sosei intends to apply drug discovery techniques such as ActivX's chemo-proteomics technology to its compounds; the companies will share in all new intellectual property developed through the collaboration; they will jointly commercialize resulting product opportunities (1/6)

Advanced Tissue Sciences Inc. (OTC BB:ATISQ)

SkinMedica Inc.

Agreement for Advanced Tissue to sell its NouriCell product line and related intellectual property to SkinMedica

Following bankruptcy court approval, SkinMedica will make a $5M cash payment to ATS and will issue a $2M, two-year promissory note (1/7)

Affinium Pharmaceuticals Inc.*

GlaxoSmithKline plc (UK)

Agreement to acquire compounds from GlaxoSmithKline, which will receive an equity stake in Affinium

Affinium is gaining worldwide discovery, development, marketing and distribution rights to compounds generated by GlaxoSmithKline's antibacterial research pro- gram; GSK gained a share of less than 20% in Affinium (2/26)

Affymetrix Inc. (AFFX)

Roche Diagnostics

A GeneChip technology license agreement

The agreement brings Affymetrix at least $70M over the next five years; Roche gets nonexclusive rights to Affymetrix's array and instrument technologies for up to 18 years and will look to develop GeneChip laboratory tests for DNA analysis, genotyping, resequencing applications and RNA expression analysis; Affymetrix receives a one-time up-front payment of $70M, amortized over five years, and would receive royalty payments on diagnostic kit sales and milestone payments for technical and commercial achievements (1/30)

Albany Molecular Research Inc. (AMRI)

Eli Lilly and Co.

Three-year natural products research collaboration focused on screening and lead identification that expands Albany Molecular's drug discovery and development technologies to include high-throughput biological screening

Lilly will transfer to Albany Molecular its natural products collection, natural product library and related databases; Albany Molecular plans to fund the costs of building an expanded screening group; it will work to discover drug lead candidates against several Lilly targets (2/13)

Alliance Pharmaceutical Corp. (ALLP)

Baxter Healthcare Corp.

Agreement with intent to give Alliance an option to purchase Baxter's ownership interest in PFC Therapeutics LLC, the joint venture established by the companies in May 2000 to commercialize Oxygent in North America and Europe

Alliance would pay Baxter a royalty on Oxygent sales by PFC, its licensees, or its assignees following regulatory approval; Alliance also would have six months to exercise its option to purchase Baxter's ownership interest in PFC; Baxter would retain a right of first offer to market Oxygent in the U.S. (1/28)

Alpha Therapeutic Corp. (subsidiary of Mitsubishi Pharma Corp.; Japan; Pink Sheets: MPHMF)

Baxter Healthcare Corp.

Agreement in which Alpha will sell certain assets to Baxter, specifically the alpha-1 antitrypsin product and all of Alpha's plasma collection operations

Alpha also will lease to Baxter facilities necessary to produce A1Pl (12/20)

Ambit Biosciences Corp.*

GlaxoSmithKline plc (UK)

Technology evaluation agreement to characterize small-molecule kinase inhibitors using Ambit's ProteomeScan platform

The work focuses on Ambit's ability to assess compound specificity by identifying protein interactions and determining binding affinities (3/4)

Ardais Corp.*

AstraZeneca plc (UK)

Licensing agreement for access to Ardais' library of human tissue samples and related information to use in drug discovery

Financial terms were not disclosed (2/4)

Astex Technology Ltd.*

AstraZeneca plc (UK)

Collaboration to discover drugs against a key target in Alzheimer's disease

AstraZeneca will pay Astex's costs and make milestone payments; the deal is worth $40M (3/3)

Atrix Laboratories Inc. (ATRX)

Sosei Co. Ltd. (Japan)

Agreement giving Sosei rights to Atrix's Eligard in Japan

Atrix receives an undisclosed up-front payment, research and development support and payments for meeting specific milestones, as well as royalty payments; the deal is worth up to $30M; Sosei will perform studies required for approval and will take care of regulatory filings; Atrix will manufacture Eligard (1/6)

Avant Immuno- therapeutics Inc. (AVAN)

Pharmacia Corp. (unit of Pfizer Corp.)

Agreement for the acquisition of intellectual property, including a portfolio of pending patent applications

The patent applications are directed to products or methods for stimulating an immune response against cholesteryl ester transfer protein, which mediates a cholesterol transport mechanism (3/10)

Beyond
Genomics Inc.*

Novartis Pharma AG (Switzerland)

Agreement under which BG will use its Systems Biology approach to analyze samples of patients with cardiovascular disease

BG will identify and characterize differences between normal and abnormal patient samples for the discovery of molecular markers to predict, diagnose and monitor the progression of cardiovascular disease; Novartis will provide BG with patient plasma samples for the program and also will provide research funding for work carried out by BG (2/11)

BioFocus plc
(UK; LSE:BIO)

Mitsubishi Pharma Corp. (Japan)

Agreement for BioFocus to provide discovery biology expertise for a high-throughput screening collaboration

Mitsubishi will transfer undisclosed assay protocols to BioFocus for primary and secondary screening; BioFocus will use its 100,000-unit screening library to identify hit molecules (2/19)

BioSante Pharmaceuticals Inc. (OTC BB: BISP)

Teva Pharmaceutical Industries Ltd. (Israel)

Development and license agreement in which Teva and BioSante will collaborate on the development of a hormone therapy product for the U.S. market

BioSante received an up-front payment of $1.5M and Teva will pay BioSante development and sales-related milestone payments, plus royalties on sales; Teva will be responsible for continued development, regulatory filings and all manufacturing and marketing associated with the product (1/6)

Biovitrum AB* (Sweden)

H Lundbeck A/S (Denmark)

Agreement for the production of a protein therapeutic

Biovitrum will assist Lundbeck in process implementation and manufacturing of material for further investigations; the agreement is for two-and-a-half years (1/14)

Bioxel Pharma
Inc.
(Canada; VSE:BIP)

Undisclosed pharmaceutical company

Collaboration to produce
a paclitaxel-derivative formulation to treat cancer and other diseases

Bioxel retains ownership of the taxane derivatives and the rights to produce them, while the partner retains ownership of the intellectual property and any patents resulting from the combination of their technologies; if a candidate is identified, Bioxel would out-license the compound for further development (1/15)

Cardion AG*
(Germany)

Pfizer Inc.

Licensing agreement for Cardion's genomics enabler technology

Pfizer will use the nonexclusive license to improve drug screening, target gene validation and predictive toxicology screening assays (2/19**)

Cell Signaling Technologies
Inc.*

Beckman
Coulter Inc.

Agreement to develop multiplex panels of activation- state-specific antibodies, and to distribute existing CST reagents and cell-signaling reagents

The antibodies will be used to explore, define and monitor major regulatory circuits controlling cell growth, differentiation and cell death using flow cytometry (2/20)

CeNeS Pharmaceuticals
plc
(UK; LSE:
CEN)

Addex Pharmaceuticals (Switzerland)

Agreement for CeNeS to partner CEE 03-310, its selective antagonist of dopamine D1 receptors being developed for the treatment of sleep disorders and substance abuse

Addex will develop the compound for drug abuse; Addex will acquire CeNeS' rights relating to CEE 03-310 and CeNeS will receive up to $4.5M in up-front and mile- stone payments; CeNeS also would receive royalties (12/19)

Cephalon Inc. (CEPH)

Tanabe Seiyaku Co. Ltd. (Japan)

Agreement to develop and commercialize Actiq

Tanabe will develop, register and market Actiq in Japan, as well as any future formulations or improvements of the product for pain in cancer patients (3/18)

Cepheid Inc. (CPHD)

Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson)

Agreement to collaborate with the Advanced Diagnostic Systems division of Ortho-Clinical in the development and sale of DNA-based tests to be run on Cepheid's SmartCycler instrument in the field of cancer

The Ortho unit will develop and commercialize a line of molecular diagnostic assays in the field of oncology (2/12)

Cerep SA*
(France)

Eli Lilly and Co.

Research collaboration for the performance of drug profiling activities and the supply of relevant information emanating from its proprietary database, BioPrint

The deal provides for Lilly and Cerep to undertake an intensive profiling program to define the chemical space that is most suitable for use in discovering lead com- pounds that are active against important target classes of pharmaceutical interest (2/26**)

Cerep SA*
(France)

Pfizer Inc.

Three-year bioinformatics agreement giving Pfizer access to Cerep's BioPrint database and the bio- informatics tools derived from it

Cerep will produce exclusive BioPrint data on a number of Pfizer compounds; Cerep received an up-front payment and will receive quarterly payments for the new data it provides (1/22**)

ChemCodes
Inc.*

Wyeth

Agreement to apply the ChemCodes chemistry platform to synthesize compounds for Wyeth

ChemCodes will use its medicinal chemistry platform that includes high-throughput chemical reactivity mapping and experimental design, among other things (1/29)

Chiron Corp.
(CHIR)

GlaxoSmithKline
plc (UK)

Partnership to fuel research in the melanocortin 4 receptor pathway

Chiron gets an up-front payment, research funding, milestone payments and royalties; at some time, GlaxoSmithKline will take over the program for clinical and commercial development (1/8)

Codexis Inc.*

Eli Lilly and Co.

Multiyear collaboration focused on the development of improved fermentation for several of Lilly's natural product drugs

The collaboration will use Codexis' Whole Genome Shuffling strain improvement technologies; Codexis will receive up- front technology access funding and full research funding, as well as milestone payments (12/20)

Compugen Ltd. (Israel; CGEN)

Abbott
Laboratories

Agreement for Abbott to use Compugen's technology for the accelerated identification of drug targets across multiple therapeutic areas

Abbott will license Compugen's LEADS computational biology platform (1/15)

Corixa Corp. (CRXA)

Purdue
Pharma LP

Licensing agreement for one of Corixa's antigens to be developed for the treatment of female reproductive tract cancer

Corixa will receive a $2.5M license fee and will potentially receive success-based mile- stones and royalties; Purdue will pay for the development and commercialization and will retain worldwide rights with an associated company (1/9)

Cytokine PharmaSciences Inc.*

Baxter Healthcare Corp.

Agreement that exclusively provides Cytokine's antimacrophage migration inhibitory factor antibody technology to Baxter

Cytokine will receive an up-front payment and potential milestones and royalties in return for giving Baxter an exclusive license to all developed indications (3/13)

Discerna Ltd.*

Undisclosed U.S. pharmaceutical company

Agreement in which Discerna will generate antibodies against a target owned by the pharmaceutical company

Further details were not disclosed (2/5**)

Discovery
Partners
International
Inc.
(DPII)

GlaxoSmithKline plc (UK)

Agreement for the delivery of a next-generation IRORI Combinatorial Chemistry Synthesis Platform

Over the next 12 months, Discovery Partners will deliver the first two next-generation X-Kan Chemistry Synthesis Systems for use at GSK sites in the UK and the U.S. (2/6)

Discovery
Partners
International
Inc.
(DPII)

Novartis AG (Switzerland)

Assay development and biological screening collaboration on several undisclosed targets

Financial terms were not disclosed (2/13)

DUSA Pharmaceuticals Inc. (DUSA)

Photonamic
GmbH & Co. KG (subsidiary of Medac GmbH; Germany)

Licensing agreement giving DUSA access to Photonamic's technology related to aminolevulinic acid

Aminolevulinic acid is the compound used in DUSA's Levulan Photodynamic Therapy and Photodetection for particular indications (1/14)

Elitra Pharmaceuticals Inc.*

Kaken Pharmaceutical Co. Ltd. (Japan)

Multiyear collaboration for the discovery and development of antifungal drugs

Elitra will conduct high-throughput screening against drug targets and will be responsible for preclinical development of any compounds; Kaken also will contribute to preclinical development, and both will focus on worldwide development efforts; Elitra retains rights in North America and certain other territories; Kaken retains rights in Japan, the Far East and Europe; Kaken makes an up-front technology access payment in the deal and will fund research at Elitra, which has the potential to receive milestone payments (2/20)

Entomed SA* (France)

Naeja Pharmaceutical
Inc.

Two-way screening agreement to identify drug targets in cancer and infectious diseases

Naeja will have access to the Entomotheque library of insect-derived molecules and analogues of Entomed for the screening of B-lactamase inhibitors; Entomed is to screen Naeja's compounds library for anti-proliferative activities (3/19**)

Epigenomics
AG*
(Germany)

Roche Diagnostics Division (Switzerland)

Three-year agreement to develop a range of molecular diagnostic and pharmacogenomic cancer products based on Epigenomics' DNA methylation technologies

Roche paid a $4.05M up-front fee and agreed to provide research and development funding, milestone payments and royalties on product sales (3/18)

Epimmune Inc. (EPMN)

Beckman Coulter Inc.

Five-year option and license agreement under which Beckman may acquire nonexclusive worldwide licenses to specific epitopes covered by Epimmune patent rights or know-how in certain infectious diseases and cancer indications

Epimmune is entitled to up-front and annual option fees; it would be entitled to additional license fees for each epitope and royalties on any product sales if Beckman exercises its option to acquire a license to any specific epitope (1/30)

Genaissance Pharmaceuticals Inc. (GNSC)

Bayer Health Care LLC (unit of Bayer AG; Germany)

Collaboration to identify pharmacogenomic markers of drug safety and efficacy

Genaissance will receive funding to apply its HAP technology to Bayer's clinical samples; Bayer will receive exclusive rights to develop and market diagnostic tests based on the results of the collaboration; Genaissance will receive unspecified royalties (1/21)

Genaissance Pharmaceuticals Inc. (GNSC)

Becton, Dickinson & Co. (NYSE: BDX)

Nonexclusive license agreement in which Genaissance will acquire a license to BD's BDProbeTec ET platform and Strand Displacement Amplification technology

The platform and technology will be used in Genaissance's CLIA-compliant diagnostic laboratory (1/24)

GeneData AG* (Switzerland)

Novartis Pharma AG (Switzerland)

Multiyear agreement to develop an integrated software platform for comprehensive visualization and analysis of high-throughput screening and compound profiling data

Novartis also acquired a license for the GeneData Screener software system on which the platform is based (1/23)

Gentris Corp.*

Sankyo Pharma
Inc. (subsidiary of Sankyo Co. Ltd.; Japan)

Partnership to further both companies' aim to make the administration of drugs to patients significantly safer and more effective

Companies agreed to a three-year collaboration; the companies also will work to develop diagnostic tests that may be important in the approval and prescribing of Sankyo's new drugs (2/24)

GPC Biotech
AG
(Germany; FSE:GPC)

Eli Lilly and Co.

Collaboration in which GPC will use LeadCode to discover the mechanism of action of compounds supplied by Lilly

Lilly is developing the compounds in the metabolic disease area (1/31)

GTC Biothera- peutics Inc.
(GTCB)

Fresenius AG (Germany)

Agreement to form a joint venture to expand the commercial development opportunities of GTC's recombinant human serum albumin (rhSA) program

The joint venture will manage the development of rhSA for the blood expander market and for the use of rhSA in the excipient market; GTC will have a majority interest in the joint venture (1/2)

GTx Inc.*

Wyeth

Agreement to further develop GTx's vesicular stomatitis virus-based technologies for use as targeted viral cytolytic agents against HIV-infected cells and cancers

Wyeth exclusively sublicensed to GTx patents covering VSV as cytolytic agents for use with GTx's VSV-based products; Wyeth has an option to commercially license GTx's VSV-based anti-HIV product, GTx-v311 (1/28)

Iconix Pharmaceuticals Inc.*

Schering-Plough Research Institute (unit of Schering AG)

Agreement to develop and validate gene markers of drug-induced organ toxicity

Iconix and SPRI will engage in a joint research program to study the genomic basis for certain forms of organ toxicity in the liver, kidney and heart (1/30)

ILEX Oncology Inc. (ILXO)

BTG
International
Ltd.

Agreement for an option from BTG for all non- oncology therapeutic uses of Campath

One major target outside of cancer is multiple sclerosis; further details were not disclosed (3/4)

Indevus Pharmaceuticals Inc. (IDEV)

Shire Pharma-
ceuticals Group
plc (UK)

Exclusive agreement under which Shire will develop extended-release formulations of trospium, a product in development for overactive bladder

The agreement includes milestone payments from Indevus to Shire, as well as royalties based on future sales of extended-release trospium; Indevus will be responsible for all development costs and commercialization (3/11)

Ingenium Pharmaceuticals AG* (Germany)

Elan Corp. plc (Ireland)

Agreement to develop therapeutics for pain management

The companies will jointly fund the four-year research programs, estimated to total $10M; Ingenium has the potential to earn up to $50M per product in success-driven milestones (3/24)

Isis Pharmaceuticals Inc. (ISIS)

Pfizer Inc.

Target validation agreement in which Pfizer will obtain access to Isis' antisense inhibitors and acquire a license to specific patents within Isis' intellectual property estate

Pfizer will use the patents in its internal antisense-based functional genomics program (1/22)

LemnaGene
LLC*

Bayer Crop- Science and Yeda Research and Development Co. Ltd. (Israel)

License agreements
to support LemnaGene's Lemnaceae-based recombinant protein production platform

The Bayer license provides enabling technologies for the production of biotherapeutics, nutraceuticals, industrial enzymes and cosmeceuticals in transgenic Lemnaceae; the Yeda agreement gives LemnaGene an exclusive license to the results of a research program and a license to Lemnaceae knowledge and technologies developed by scientists at the Weizmann Institute of Science (3/24)

LION bioscience
AG
(Germany; LEON)

AstraZeneca plc (UK)

Global perpetual license agreement for LION's SRS integration technology modules aimed at better drug discovery

Financial terms were not disclosed (2/12)

LION bioscience
AG
(Germany; LEON)

Eli Lilly and Co.

Global licensing agreement for LIONS's SRS integration technology modules aimed at better drug discovery

LION's SRS is a data-integration platform that provides access to genetic, protein, cellular, molecular and clinical data for genomics research (1/17)

LION bioscience
AG
(Germany; LEON)

Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson)

Two-year global licensing agreement for LION's SRS integration technology

J&J will access LION's SRS7.0 software and SRS Prisma (1/22)

Luminex Corp. (LMNX)

Abbott
Laboratories

Agreements granting Abbott license, supply and distribution rights to Luminex biological testing technologies

The license agreement grants Abbott a worldwide license under Luminex patents, including Luminex's bead-based xMAP technology, for the development of assays and instruments; Abbott also has rights to purchase and distribute Luminex products (1/16)

MDL Information Systems Inc.*

Boehringer Ingelheim GmbH (Germany)

Long-term agreement to provide software technology for managing and deploying chemical information systems

The agreement covers a package of MDL Discovery Framework technology, including the MDL Relational Chemistry Server (3/19)

MDS Proteomics Inc. (Canada; subsidiary of MDS Inc.; NYSE:MDZ)

Eli Lilly Canada
Inc. (Canada)

Agreement to explore the use of MDSP's technology called PhosMap

The pilot study will focus on Lilly's drug candidates and is designed to assess the capability of the technology to determine the effects of kinase inhibitors on kinase targets that may span several therapeutic areas (1/14)

MedActinium
Inc.*
(subsidiary
of Actinium Pharmaceuticals Inc.)

Battelle

Collaboration in the alpha particle immunotherapy field

Financial details were not disclosed (1/29)

Medarex Inc. (MEDX)

Abbott
Laboratories

Multiyear agreement under which Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to disease targets supplied by Abbott

Medarex could receive license fees and milestone payments, as well as royalties on sales of any products resulting from the agreement; therapeutic areas of focus include immunology, oncology, neuroscience, metabolics and infectious diseases (1/21)

MerLion Pharmaceuticals Pte. Ltd.* (Singapore)

Merck & Co. Inc.

Collaboration centered on drugs from natural sources

MerLion will screen its natural product collection using assays provided by Merck, which will progress compounds through development and will market any products worldwide; MerLion is scheduled to receive milestone payments, as well as royalties (2/13)

Microbia Inc.* Engineering technology

Ranbaxy Laboratories Ltd. (India)

Collaboration to develop improved, higher-yielding biomanufacturing processes using Microbia's Precision

The objective is to apply the technology to produce pharmaceuticals with high efficiency and purity and to accelerate the process development cycle (2/25)

Molecular
Staging Inc.*

Eli Lilly and Co.

Clinical proteomics research collaboration in which MSI will use its clinical proteomics platform and bioinformatics to identify biomarkers in the rapid progression of sepsis

The goal is to identify opportunities for earlier intervention and improved patient outcomes (1/27)

MorphoSys AG (Germany; Neuer Markt: MOR)

Boehringer Ingelheim GmbH (Germany)

Therapeutic antibody collaboration and cross- license agreement in which MorphoSys receives an exclusive worldwide license to patents owned or controlled by Boehringer Ingelheim to develop, make and sell therapeutic and diagnostic antibodies targeting the ICAM-1 molecule

Boehringer Ingelheim will receive exclusive commercial licenses to antibodies against two undisclosed targets, which MorphoSys will generate using its HuCAL Gold antibody technology; MorphoSys will make milestone and royalty payments to Boehringer Ingelheim, which will make milestone and royalty payments back to MorphoSys for the development and sale of HuCAL antibodies delivered by MorphoSys (2/25)

MRL International (division of PPD Development Inc.; PPDI)

Bayer AG (Germany)

Agreement granting to MRL International, a division of PPD, worldwide rights to undertake additional Phase I and II studies on implitapide

MRLI will have access to Bayer's existing information from preclinical studies and previously conducted trials, as well as regulatory filings to conduct trials in the U.S., Europe and South Africa (1/7)

MultiCell Technologies Inc. (subsidiary of Exten Industries Inc.; OTC BB: EXTIE)

Unnamed pharmaceutical company

Agreement in which the pharmaceutical company may use two of MultiCell's liver cell lines for a variety of internal research programs for 15 years

Multicell will receive an undisclosed fee and periodic renewal fees (2/3)

Neurion Pharmaceuticals Inc.*

Pfizer Inc.

Research agreement to develop experimentally based computational models of drug binding interactions with the HERG potassium ion channel

Neurion and Pfizer will use those models to aid in the development of new drugs designed to have a reduced risk of potentially dangerous cardiac side effects (1/15)

Neurocrine Biosciences Inc. (NBIX)

Pfizer Inc.

Licensing agreement for a late-stage compound to treat insomnia

The deal is worth more than $400M for Neurocrine, which licensed to Pfizer exclusive worldwide development and commercialization rights to indiplon; Pfizer also will create a sales force at Neurocrine that eventually will sell indiplon and Pfizer's antidepressant drug, Zoloft (12/19)

NiKem
Research*
(Italy)

GlaxoSmithKline plc (UK)

Agreement in which NiKem acquired a patent portfolio from GlaxoSmithKline

The portfolio includes three new chemical classes of small-molecule inhibitors of the vacuolar proton ATPase (2/27)

NitroMed Inc.*

Merck & Co. Inc.

Multiyear research collaboration to develop nitric oxide-based medicines

The research will focus on the treatment and prevention of cardiovascular and inflammatory diseases; Merck will invest in NitroMed's research program, and will pay an up-front fee, certain research-based milestone payments and royalty payments (1/8)

Norak
Biosciences

Inc.*

H. Lundbeck A/S (Denmark)

Collaboration to use Norak's Transfluor technology for G protein- coupled receptor drug discovery

Norak will develop Transfluor cell lines expressing GPCR targets of interest to Lund- beck and then screen the lines on its high-throughput imaging systems against its large compound library; Norak will receive licensing, assay development and screening fees, as well as milestone payments and royalties (1/8)

Novozymes A/S* (Denmark)

Solvay Pharmaceuticals
BV (Belgium)

Agreement in which Novozymes sold to Solvay patents related to the production of a recombinant enzyme for pharmaceutical specialties

Novozymes, which retained the right to develop, manufacture and market the specific enzyme outside this field, will receive a minor up-front payment; Novozymes is entitled to potential royalties if the enzyme is marketed (12/20)

OncoMab GmbH* (Germany)

H3 Pharma Inc. (Canada)

Licensing agreement
for SC-1

The deal includes an exclusive, royalty-bearing license for SC-1 and its molecular target, and an exclusive option for a license on three other products targeting other forms of cancer; H3 Pharma will take charge of clinical development and worldwide registration for the four products (3/17)

Orchid
BioSciences Inc.
(ORCH)

Beckman
Coulter Inc.

Agreement in which Beckman Coulter is buying Orchid's single nucleotide polymorphism genotyping instruments and related consumables

Orchid receives undisclosed cash payments and certain debt assumption; Beckman Coulter will assume certain obligations to third parties related to Orchid's reagents and instrument leases (12/20)

Oxford
BioMedica plc
(UK; LSE:OXB)

Wyeth

Exercised option agree-
ment for an exclusive license to an Oxford BioMedica antibody against a tumor- associated antigen in all human cancer indications

The move triggers an undisclosed mile- stone payment; Wyeth has rights to develop the antibody alone or conjugated with the cytotoxic calicheamicin (3/12**)

Peplin Biotech
Ltd.*
(Australia)

Allergan Inc.

Collaboration and license agreement for the exclusive right to develop and commercialize PEP005 in North and South America for the topical treatment of non-melanoma skin cancer and actinic keratosis

Peplin may receive up to $23M in mile- stone and other payments, and sales royalties (11/25)

Peregrine Pharmaceuticals Inc. (PPHM)

Schering AG (Germany)

Worldwide, exclusive licensing agreement for the development of diagnostic and imaging agents in the field of oncology

Schering will have the right to develop and commercialize VTA-based imaging and diagnostic agents for oncology (1/6)

Perlegen
Sciences Inc.*

Bristol-Myers Squibb Co.

Collaboration to identify markers of patient response to medications in Bristol-Myers' portfolio

Perlegen will use high-resolution whole-genome association technologies and a portfolio of more than 1.5M Perlegen-identified single nucleotide polymorphisms in the study; Bristol-Myers will provide Perlegen with undisclosed research funding, milestone payments and royalties (12/19)

Perlegen
Sciences Inc.*

Eli Lilly and Co.

Agreement in which Perlegen will use its technology to identify genetic markers for Lilly

Perlegen will receive undisclosed research funding, plus potential milestone payments and royalties (12/19)

Perlegen
Sciences Inc.*

Pfizer Inc.

Research collaboration todiscover the human geneticcontributions to cardiovascular disease

Perlegen will employ its high-density genotyping technologies and knowledge of human genetic variation to identify genes and other genetic loci associated with cardiovascular disease (12/20)

Pharmacopeia
Inc.
(PCOP)

Novartis AG (Switzerland)

Collaboration in which the companies will work to identify lead compounds against multiple drug targets from Novartis' discovery programs

Novartis will pay for Pharmacopeia's services along the way; there also could be milestone and royalty payments (2/3)

Pharmagenesis Inc.*

Pierre-Fabre Medicament (division of Bio- Merieux Pierre Fabre; France)

Agreement to license PG490-88Na, a patented derivative of a compound from a plant used in Chinese medicine

Pierre-Fabre gained worldwide rights to develop, register, manufacture, market and sell PG490-88Na, except in Taiwan, China and Hong Kong (3/17)

Phytomedics
Inc.*

SK Chemicals Life Science R&D Center (unit of SK Group; South Korea)

Agreement to start the joint testing of new prescription botanical drugs for the global pharmaceutical markets

Further details were not disclosed (1/7)

Prana Biotechnology
Ltd.
(Australia; PRAN)

Schering AG (Germany)

Agreement for Schering
to fund and license discoveries of new drug targets, especially in the area of diagnostics

The agreement is part of a larger deal between Prana and Neuroscience Victoria; about A$7.5M (US$4.4M) will be provided for discovery research; deal also includes potential milestone payments and royalties (3/19)

Protea
Biosciences Inc.*

Novartis Pharmaceuticals Corp.
(Switzerland)

Contract agreement to
provide proteomics services to Novartis

Protea will apply its proteomics technology to the collaboration, which is focused on identifying protein biomarkers present in human sera that will allow physicians to identify specific cancers earlier (1/8)

Sagres
Discovery Inc.*

Boehringer Ingelheim International
GmbH (Germany)

Research collaboration to identify oncology drug targets

Sagres will apply mouse tumor biology and in vivo screening technology coupled with bioinformatics to identify targets; Boehringer receives exclusive rights to certain targets and will develop and market monoclonal antibody and small-molecule products worldwide, primarily in the oncology area; Sagres will retain rights to certain targets, and will receive an up-front payment, committed research funding and milestone and royalty payments on any resulting sales (1/9)

Sangamo BioSciences Inc. (SGMO)

Purdue
Pharma LP

Agreement for Sangamo
to provide its zinc finger DNA-binding protein transcription factors for use in the research and drug discovery program of Purdue Pharma

Financial terms were not disclosed (1/21)

Structural
GenomiX Inc.*

Boehringer Ingelheim Pharmaceuticals Inc.

Two-year agreement for Structural GenomiX's structure-directed drug discovery technologies to support Boehringer's lead-optimization activities

Financial details were not disclosed (1/15)

Sunesis Pharmaceuticals Inc.*

Merck & Co.
Inc.

Multiyear research collaboration to discover oral therapeutics to treat Alzheimer's disease

Sunesis will receive an undisclosed upfront payment, research funding and a series of milestone payments; Merck gains exclusive, worldwide rights to any resulting products, and would make royalty payments based on net sales (2/19)

Symyx Technologies Inc. (SMMX)

Eli Lilly and Co.

Agreement for the delivery and installation of a Polymorph Discovery Tools System

Symyx installed the system with Lilly; financial terms were not disclosed (12/19)

TaiGen Biotechnology Co. Ltd.* (Taiwan)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Licensing and collaborative agreement in which Tai- Gen grants Fujisawa non- exclusive rights to a G protein-coupled receptor drug target and a screen- ready, high-throughput screening assay system for the discovery of drugs for immune and inflammatory diseases

TaiGen retains the rights for some other indications, including hepatitis; companies will conduct research and development of lead compounds resulting from the drug target screening (2/24)

Theravance
Inc.*

GlaxoSmithKline plc (UK)

Agreement to develop treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease

The companies will pool their long-acting beta 2 agonists to develop the treatments; the deal is worth $545M for Theravance, with $50M up front and another potential $495M in milestone payments (1/6)

TheRyte Ltd.* (UK)

Randox Laboratories Ltd.

Technology license and commercialization deal for marker tests in cancer

The deal is for the development of proteomics-based, early stage diagnostic and theranostic marker tests for cancer using TheRyte's technology (3/14)

Transgene SA (France; TRGNY)

Merck & Co. Inc.

Nonexclusive license agreement for Transgene's patents that claim methods for the preparation of recombinant viral vectors, in particular adenovirus vectors, by intermolecular homologous recombination

The technology is designed to enable the generation of adenovirus vectors; Transgene will receive an initial license fee, annual maintenance fees and possible milestone payments, as well as royalties (2/3)

Valentis Inc.
(VLTS)

Prolong Pharmaceuticals

Licensing agreement for use of the OptiPEG PEGylation platform in the development and commercialization of PEGylated protein therapeutics

The agreement was made through Valentis' wholly owned subsidiary, PolyMASC Pharmaceuticals plc; further details were not disclosed (2/10)

Valentis Inc.
(VLTS)

Schering AG (Germany)

Agreement to develop gene-based therapeutic products

Schering obtains exclusive, worldwide rights to use two Valentis platform technologies, PINC polymer-based synthetic gene delivery and the GeneSwitch gene regulation technologies; an initial $1.1M cash payment covers license and option fees; additional financial details were not disclosed (12/20)

Xenogen
Corp.*

NV Organon (the Netherlands)

Licensing and lease agreement in which Organon will use Xenogen's biophotonic imaging technology and LPTA animal models to study potential drug candidates

The commercial license extends the terms of the original agreement with Organon and expands Organon's use of Xenogen's imaging technology (1/28)

XenoPort Inc.*

ALZA Corp.

Collaboration to develop drugs that combine XenoPort's active transport technologies and ALZA's oral drug delivery technologies

The companies intend to improve three existing products that can be better absorbed throughout the gastrointestinal tract; ALZA will further develop the prodrugs to create products with improved pharmacokinetic and therapeutic profiles; ALZA will make an up-front payment to XenoPort, and will fund research and development, as well as pay for the achievement of milestones; XenoPort also would receive potential royalties (1/7)

ZymoGenetics
Inc.
(ZGEN)

Novo Nordisk A/S (Denmark)

Collaboration for the preclinical development of interleukin-21

Novo Nordisk will license IL-21 for areas outside of North America; the companies will collaborate on the research and development activities leading up to an investigational NDA that ZymoGenetics would file; Novo will reimburse ZymoGenetics for a portion of costs incurred, but the companies will share costs going forward; the deal is worth $11M for ZymoGenetics (1/9)

Zyomyx Inc.*

Aventis SA
(France)

Agreement for Aventis to purchase Zyomyx's complete Protein Profiling Biochip System, featuring Zyomyx's first protein profiling biochip, the Human Cytokine Biochip

Aventis will apply the system to its programs in inflammation (3/6)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; VSE = Vancouver Stock Exchange